| 1 |
34319003 |
10.1002/cnr2.1524 |
2022 |
Serum proteome modulations upon treatment provides biological insight on response to treatment in relapsed mantle cell lymphoma. |
BTK |
| 2 |
34332791 |
10.1016/j.pathol.2021.04.008 |
2022 |
Morphologic and molecular analysis of Richter syndrome in chronic lymphocytic leukaemia patients treated with ibrutinib or venetoclax. |
BTK |
| 3 |
34615723 |
10.1158/1078-0432.CCR-21-2183 |
2022 |
Phase I/Ib Study of the Efficacy and Safety of Buparlisib and Ibrutinib Therapy in MCL, FL, and DLBCL with Serial Cell-Free DNA Monitoring. |
BTK |
| 4 |
34638136 |
10.1182/bloodadvances.2020003698 |
2022 |
Zanubrutinib monotherapy for relapsed or refractory non-germinal center diffuse large B-cell lymphoma. |
BTK |
| 5 |
34679161 |
10.1182/blood.2021013326 |
2022 |
Therapeutic options for relapsed/refractory mantle cell lymphoma. |
BTK |
| 6 |
34713475 |
10.1002/hon.2943 |
2022 |
Treatment strategies for a rapidly evolving landscape in chronic lymphocytic leukemia management. |
BTK |
| 7 |
34714908 |
10.1182/bloodadvances.2021005486 |
2022 |
Integrative genomic and transcriptomic analysis in plasmablastic lymphoma identifies disruption of key regulatory pathways. |
BTK |
| 8 |
34724705 |
10.1182/bloodadvances.2021005621 |
2022 |
Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies. |
BTK |
| 9 |
34774461 |
10.1016/j.clml.2021.09.012 |
2022 |
SOHO State of the Art Updates and Next Questions: BTK inhibitors combined with chemoimmunotherapy in CLL, the best of both worlds? |
BTK |
| 10 |
34783281 |
10.1080/10428194.2021.1999444 |
2022 |
Targeting MALT1 for the treatment of diffuse large B-cell lymphoma. |
BTK |
| 11 |
34795418 |
10.1038/s41375-021-01470-4 |
2022 |
Inhibitors of Bcl-2 and Bruton's tyrosine kinase synergize to abrogate diffuse large B-cell lymphoma growth in vitro and in orthotopic xenotransplantation models. |
BTK |
| 12 |
34817087 |
10.1002/hon.2952 |
2022 |
Outcome of patients with mantle cell lymphoma after autologous stem cell transplantation in the pre-CAR T-cell era. |
BTK |
| 13 |
34821081 |
10.1002/cnr2.1590 |
2022 |
Mantle cell lymphoma: A clinical review of the changing treatment paradigms with the advent of novel therapies, and an insight into Indian data. |
BTK |
| 14 |
34838186 |
10.1016/j.ccell.2021.11.006 |
2022 |
Efficacy of booster doses in augmenting waning immune responses to COVID-19 vaccine in patients with cancer. |
BTK |
| 15 |
34839996 |
10.1016/j.ejmech.2021.114009 |
2022 |
Review of the development of BTK inhibitors in overcoming the clinical limitations of ibrutinib. |
BTK |
| 16 |
34843717 |
10.1016/j.bcp.2021.114861 |
2022 |
Luxeptinib disables NLRP3 inflammasome-mediated IL-1β release and pathways required for secretion of inflammatory cytokines IL-6 and TNFα. |
BTK |
| 17 |
34861036 |
10.1182/blood.2021014085 |
2022 |
Efficacy of a third BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL who failed standard 2-dose vaccination. |
BTK |
| 18 |
34861696 |
10.1182/bloodadvances.2021006211 |
2022 |
Single-cell sequencing demonstrates complex resistance landscape in CLL and MCL treated with BTK and BCL2 inhibitors. |
BTK |
| 19 |
34905129 |
10.1007/s11523-021-00857-8 |
2022 |
Bruton Tyrosine Kinase Inhibitors in B-Cell Malignancies: Their Use and Differential Features. |
BTK |
| 20 |
34910982 |
10.1016/j.bioorg.2021.105541 |
2022 |
Discovery of pyrido[3,4-b]indol-1-one derivatives as novel non-covalent Bruton's tyrosine kinase (BTK) inhibitors. |
BTK |
| 21 |
34932207 |
10.1007/s40265-021-01657-0 |
2022 |
Current Treatment of Chronic Lymphocytic Leukemia: The Diminishing Role of Chemoimmunotherapy. |
BTK |
| 22 |
34980578 |
10.1016/j.clml.2021.11.014 |
2022 |
SOHO State of the Art Updates and Next Questions: Waldenström Macroglobulinemia - 2021 Update on Management and Future Directions. |
BTK |
| 23 |
35031886 |
10.1186/s43556-021-00066-9 |
2022 |
Combinatorial inhibition of BTK, PI3K-AKT and BRD4-MYC as a strategy for treatment of mantle cell lymphoma. |
BTK |
| 24 |
35068379 |
10.1080/16078454.2021.2019363 |
2022 |
Application of new targeted drugs in relapsed/refractory primary central nervous system lymphoma. |
BTK |
| 25 |
35076567 |
10.3390/neurolint14010009 |
2022 |
Ibrutinib in Refractory or Relapsing Primary Central Nervous System Lymphoma: A Systematic Review. |
BTK |
| 26 |
35078814 |
10.1158/0008-5472.CAN-21-0218 |
2022 |
Targeting Cellular Iron Homeostasis with Ironomycin in Diffuse Large B-cell Lymphoma. |
BTK |
| 27 |
35096069 |
10.1155/2022/1182384 |
2022 |
Utility of Bruton's Tyrosine Kinase Inhibitors in Light Chain Amyloidosis Caused by Lymphoplasmacytic Lymphoma (Waldenström's Macroglobulinemia). |
BTK |
| 28 |
35115740 |
10.1007/s12288-021-01433-w |
2022 |
Ibrutinib in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Retrospective Study. |
BTK |
| 29 |
35123927 |
10.1016/j.clml.2022.01.008 |
2022 |
SOHO State of the Art Updates and Next Questions: Managing Relapsed Mantle Cell Lymphoma. |
BTK |
| 30 |
35139644 |
10.2217/fon-2021-0602 |
2022 |
Acalabrutinib and its use in the treatment of chronic lymphocytic leukemia. |
BTK |
| 31 |
35149375 |
10.1016/j.ctarc.2022.100527 |
2022 |
Current approach to Waldenström Macroglobulinemia. |
BTK |
| 32 |
35169086 |
10.11477/mf.1436204531 |
2022 |
[Perspectives on Precision Medicine in Primary Central Nervous System Lymphoma]. |
BTK |
| 33 |
35184664 |
10.1080/17474086.2022.2044778 |
2022 |
Management of relapsed or refractory large B-cell lymphoma in patients ineligible for CAR-T cell therapy. |
BTK |
| 34 |
35188143 |
10.1358/dot.2022.58.2.3360405 |
2022 |
Research progress in overcoming ibrutinib drug resistance. |
BTK |
| 35 |
35196427 |
10.1056/NEJMoa2114110 |
2022 |
Mechanisms of Resistance to Noncovalent Bruton's Tyrosine Kinase Inhibitors. |
BTK |
| 36 |
35205606 |
10.3390/cancers14040860 |
2022 |
Regulation of B-Cell Receptor Signaling and Its Therapeutic Relevance in Aggressive B-Cell Lymphomas. |
BTK |
| 37 |
35230873 |
10.1126/scisignal.abk3083 |
2022 |
Phosphorylation of serine-893 in CARD11 suppresses the formation and activity of the CARD11-BCL10-MALT1 complex in T and B cells. |
BTK |
| 38 |
35237395 |
10.1177/20406207221080738 |
2022 |
Chimeric antigen receptor (CAR) T-cell treatment for mantle cell lymphoma (MCL). |
BTK |
| 39 |
35247223 |
10.1002/hon.2983 |
2022 |
Use of BTK inhibitors with focus on ibrutinib in mantle cell lymphoma: An expert panel opinion statement. |
BTK |
| 40 |
35247800 |
10.1016/j.thromres.2022.02.020 |
2022 |
The effect of Bruton's tyrosine kinase inhibitor ibrutinib on atherothrombus formation under stenotic flow conditions. |
BTK |
| 41 |
35255496 |
10.1182/bloodadvances.2021006147 |
2022 |
A new role for the SRC family kinase HCK as a driver of SYK activation in MYD88 mutated lymphomas. |
BTK |
| 42 |
35266562 |
10.1002/ajh.26523 |
2022 |
Mantle cell lymphoma in 2022-A comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments. |
BTK |
| 43 |
35273899 |
10.1055/s-0042-1744128 |
2022 |
Spontaneous Spinal Subdural Hematoma Secondary to Hemophilia A and Zanubrutinib. |
BTK |
| 44 |
35294723 |
10.1007/s11864-022-00973-1 |
2022 |
Novel Approaches for the Treatment of Patients with Richter's Syndrome. |
BTK |
| 45 |
35296646 |
10.1038/s41419-022-04684-1 |
2022 |
Dual BTK/SYK inhibition with CG-806 (luxeptinib) disrupts B-cell receptor and Bcl-2 signaling networks in mantle cell lymphoma. |
BTK |
| 46 |
35303070 |
10.1182/blood.2021014162 |
2022 |
Zanubrutinib in relapsed/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study. |
BTK |
| 47 |
35306137 |
10.1016/j.cellsig.2022.110311 |
2022 |
B-cell receptor signaling induces proteasomal degradation of PDCD4 via MEK1/2 and mTORC1 in malignant B cells. |
BTK |
| 48 |
35306909 |
10.1177/10781552221087730 |
2022 |
A fatal disseminated cryptococcal infection in a patient treated with zanubrutinib for Waldenström's macroglobulinemia. |
BTK |
| 49 |
35313381 |
10.1002/hon.2986 |
2022 |
Phase II study of fixed-duration single-agent ibrutinib in relapsed nodular lymphocyte-predominant Hodgkin lymphoma: A report from the German Hodgkin Study Group. |
BTK |
| 50 |
35326604 |
10.3390/cancers14061453 |
2022 |
DLBCL 1L-What to Expect beyond R-CHOP? |
BTK |
| 51 |
35330376 |
10.3390/jpm12030376 |
2022 |
Relapsed/Refractory Mantle Cell Lymphoma: Beyond BTK Inhibitors. |
BTK |
| 52 |
35339405 |
10.1016/j.clml.2022.02.005 |
2022 |
SOHO State of the Art Updates and Next Questions: Targeted therapies and emerging novel treatment approaches for Waldenström Macroglobulinemia. |
BTK |
| 53 |
35341452 |
10.1080/10428194.2022.2056179 |
2022 |
Incidence of <i>Pneumocystis jirovecii</i> pneumonia (PJP) in patients receiving BTK inhibitors who did not receive PJP prophylaxis. |
BTK |
| 54 |
35350909 |
10.1177/10781552221090869 |
2022 |
Real-world management of targeted therapies in chronic lymphocytic leukemia. |
BTK |
| 55 |
35357653 |
10.1007/s11864-022-00974-0 |
2022 |
New Treatment Options for Newly-Diagnosed and Relapsed Chronic Lymphocytic Leukemia. |
BTK |
| 56 |
35379357 |
10.1186/s40364-022-00357-5 |
2022 |
Combining BTK inhibitors with BCL2 inhibitors for treating chronic lymphocytic leukemia and mantle cell lymphoma. |
BTK |
| 57 |
35383885 |
10.1111/bjh.18162 |
2022 |
A two-part, single-arm, multicentre, phase I study of zanubrutinib, a selective Bruton tyrosine kinase inhibitor, in Chinese patients with relapsed/refractory B-cell malignancies. |
BTK |
| 58 |
35403972 |
10.1007/s11912-022-01250-y |
2022 |
Targeting The Tumor Microenvironment in Lymphomas: Emerging Biological Insights and Therapeutic Strategies. |
BTK |
| 59 |
35404729 |
10.1080/14737140.2022.2064849 |
2022 |
Zanubrutinib for the treatment of adults with Waldenstrom macroglobulinemia. |
BTK |
| 60 |
35411248 |
|
2022 |
PIK-75 overcomes venetoclax resistance <i>via</i> blocking PI3K-AKT signaling and MCL-1 expression in mantle cell lymphoma. |
BTK |
| 61 |
35411950 |
10.1002/cbf.3702 |
2022 |
USP7 sustains an active epigenetic program via stabilizing MLL2 and WDR5 in diffuse large B-cell lymphoma. |
BTK |
| 62 |
35435617 |
10.1007/s11864-022-00953-5 |
2022 |
Chronic Lymphocytic Leukemia: Chemotherapy Free and Other Novel Therapies Including CAR T. |
BTK |
| 63 |
35437106 |
10.1080/17474086.2022.2067526 |
2022 |
Cardiotoxicity of BTK inhibitors: ibrutinib and beyond. |
BTK |
| 64 |
35440579 |
10.1038/s41467-022-29835-y |
2022 |
A loss-of-adhesion CRISPR-Cas9 screening platform to identify cell adhesion-regulatory proteins and signaling pathways. |
BTK |
| 65 |
35450208 |
10.1177/20406207221090886 |
2022 |
Updates in hairy cell leukemia (HCL) and variant-type HCL (HCL-V): rationale for targeted treatments with a focus on ibrutinib. |
BTK |
| 66 |
35465824 |
10.1080/10428194.2022.2064995 |
2022 |
The role of BTK inhibitors on the tumor microenvironment in CLL. |
BTK |
| 67 |
35474969 |
10.1097/HS9.0000000000000715 |
2022 |
New Mechanisms of Genomic Escape From Noncovalent BTK Inhibitors. |
BTK |
| 68 |
35482146 |
10.1007/s11307-022-01733-1 |
2022 |
[<sup>18</sup>F]BTK-1: A Novel Positron Emission Tomography Tracer for Imaging Bruton's Tyrosine Kinase. |
BTK |
| 69 |
35510210 |
10.1177/20406207221093962 |
2022 |
Treatment paradigm in Waldenström macroglobulinemia: frontline therapy and beyond. |
BTK |
| 70 |
35558005 |
10.1177/17588359221093745 |
2022 |
Novel insights into the biomarkers and therapies for primary central nervous system lymphoma. |
BTK |
| 71 |
35561314 |
10.1182/bloodadvances.2022007247 |
2022 |
Evaluating real-world treatment patterns and outcomes of mantle cell lymphoma. |
BTK |
| 72 |
35571529 |
10.1155/2022/1930546 |
2022 |
Ibrutinib Plus R-ICE Induces Remission in Blastoid Variant Mantle Cell Lymphoma with CNS Relapse. |
BTK |
| 73 |
35577753 |
10.1016/j.clml.2022.04.017 |
2022 |
SOHO State of the Art Updates and Next Questions | Management of Most Difficult Cases of Chronic Lymphocytic Leukemia: Relapse After Both BTK and BCL2 Inhibition and Richter Transformation. |
BTK |
| 74 |
35596920 |
10.1007/s11912-022-01286-0 |
2022 |
BTK Inhibitors and CAR T-Cell Therapy in Treating Mantle Cell Lymphoma-Finding a Dancing Partner. |
BTK |
| 75 |
35597428 |
10.1016/j.cellsig.2022.110358 |
2022 |
BTK-independent regulation of calcium signalling downstream of the B-cell receptor in malignant B-cells. |
BTK |
| 76 |
35628381 |
10.3390/ijms23105570 |
2022 |
<i>MYD88</i> Mutations: Transforming the Landscape of IgM Monoclonal Gammopathies. |
BTK |
| 77 |
35639332 |
10.1007/s11912-022-01297-x |
2022 |
Mantle Cell Lymphoma: the Role of Risk-Adapted Therapy and Treatment of Relapsed Disease. |
BTK |
| 78 |
35651781 |
10.1177/20406207221093980 |
2022 |
Zanubrutinib in lymphoproliferative disorders: a comprehensive review. |
BTK |
| 79 |
35658124 |
10.1158/2159-8290.CD-21-1566 |
2022 |
BCL10 Mutations Define Distinct Dependencies Guiding Precision Therapy for DLBCL. |
BTK |
| 80 |
35670706 |
10.1358/dot.2022.58.6.3378055 |
2022 |
Brexucabtagene autoleucel: a breakthrough in the treatment of mantle cell lymphoma. |
BTK |
| 81 |
35671249 |
10.1021/acs.jmedchem.2c00324 |
2022 |
Structural Feature Analyzation Strategies toward Discovery of Orally Bioavailable PROTACs of Bruton's Tyrosine Kinase for the Treatment of Lymphoma. |
BTK |
| 82 |
35680835 |
10.19746/j.cnki.issn.1009-2137.2022.03.049 |
2022 |
[Clinical Application of Zanubrutinib in B-Cell Lymphoma --Review]. |
BTK |
| 83 |
35714675 |
10.6004/jnccn.2022.0031 |
2022 |
NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 3.2022. |
BTK |
| 84 |
35721157 |
10.3389/fphar.2022.864194 |
2022 |
HSP90 Inhibitor Ganetespib Enhances the Sensitivity of Mantle Cell Lymphoma to Bruton's Tyrosine Kinase Inhibitor Ibrutinib. |
BTK |
| 85 |
35745866 |
10.3390/pharmaceutics14061294 |
2022 |
Design, Synthesis, In Silico Studies and Inhibitory Activity towards Bcr-Abl, BTK and FLT3-ITD of New 2,6,9-Trisubstituted Purine Derivatives as Potential Agents for the Treatment of Leukaemia. |
BTK |
| 86 |
35757723 |
10.3389/fimmu.2022.894787 |
2022 |
Case Report: Dual Inhibition of HDAC and BTK for Diffuse Large B-Cell Lymphoma After Failure to CD19-Targeted CAR-T Therapy. |
BTK |
| 87 |
35770040 |
10.2147/TCRM.S338655 |
2022 |
Zanubrutinib in Treating Waldenström Macroglobulinemia, the Last Shall Be the First. |
BTK |
| 88 |
35785180 |
10.3389/fonc.2022.901797 |
2022 |
Orelabrutinib Combined With Lenalidomide and Immunochemotherapy for Relapsed/Refractory Primary Central Nervous System Lymphoma: A Retrospective Analysis of Case Series. |
BTK |
| 89 |
35804999 |
10.3390/cancers14133229 |
2022 |
Tumor Microenvironment and Immunotherapy-Based Approaches in Mantle Cell Lymphoma. |
BTK |
| 90 |
35836543 |
10.21037/tcr-22-1375 |
2022 |
A case report of acquired immunodeficiency syndrome (AIDS)-related refractory Burkitt lymphoma got complete remission by multidisciplinary and multi-target combined therapy. |
BTK |
| 91 |
35852229 |
10.1080/10428194.2022.2098289 |
2022 |
Practical management of chronic lymphocytic leukemia with acalabrutinib. |
BTK |
| 92 |
35908982 |
10.1016/j.blre.2022.100992 |
2022 |
Follicular lymphoma: The long and winding road leading to your cure? |
BTK |
| 93 |
35911566 |
10.2147/BLCTT.S326627 |
2022 |
Use of BTK Inhibitors in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): A Practical Guidance. |
BTK |
| 94 |
35937468 |
10.6004/jadpro.2022.13.5.14 |
2022 |
A Focus on Waldenström Macroglobulinemia and AL Amyloidosis. |
BTK |
| 95 |
35941532 |
10.1186/s10020-022-00518-0 |
2022 |
Interfering B cell receptor signaling via SHP-1/p-Lyn axis shows therapeutic potential in diffuse large B-cell lymphoma. |
BTK |
| 96 |
35956064 |
10.3390/jcm11154447 |
2022 |
Bing-Neel Syndrome, a Rare Presentation of Waldenström Macroglobulinemia-A Multicenter Report by the Polish Lymphoma Research Group. |
BTK |
| 97 |
35957865 |
10.3389/fonc.2022.941633 |
2022 |
Case report: Zanubrutinib-induced dermatological toxicities: A single-center experience and review. |
BTK |
| 98 |
35973369 |
10.1016/j.intimp.2022.109138 |
2022 |
Zanubrutinib ameliorates lipopolysaccharide-induced acute lung injury via regulating macrophage polarization. |
BTK |
| 99 |
35975476 |
10.1002/hon.3056 |
2022 |
Ibrutinib combined with low-dose histone deacetylases inhibitor chidamide synergistically enhances the anti-tumor effect in B-cell lymphoma. |
BTK |
| 100 |
35979372 |
10.3389/fimmu.2022.943354 |
2022 |
Regulatory T cells (Tregs) in lymphoid malignancies and the impact of novel therapies. |
BTK |
Datasets
Models
